Top Story Today
Lilly's Factory-Free CAR-T Just Went 18-for-18. The Implications Are Enormous.
Every single patient responded. At ASCO 2026, Kelonia Therapeutics (acquired by Lilly for up to $7 billion) showed that all 18 evaluable patients on its in vivo CAR-T therapy KLN-1010 achieved MRD-negative status, the deepest measurable response in multiple myeloma. The kicker: only two ICANS (neurotoxicity) events—one Grade 1 and one Grade 3 lasting 3 days—and only mild immune reactions, which could make this an outpatient treatment. Traditional CAR-T requires extracting a patient's cells, shipping them to a factory, and waiting weeks. KLN-1010 skips all of that with a single IV infusion that reprograms your immune cells inside your body.
Why it matters: If in vivo CAR-T can match these results in larger trials, it could transform cell therapy from a $500,000 bespoke procedure at elite hospitals into a standard infusion available anywhere. That's a potential paradigm shift for millions of cancer patients worldwide who currently can't access the treatment.
Read more →ASCO and AACR: The Clinical Data Drops
Two Pharma Giants, One Drug Class, Totally Different Gambles
BioNTech/BMS and Pfizer are both building bispecific antibodies to challenge Keytruda in lung cancer, but they just split on the most consequential decision in trial design. BioNTech/BMS will bet everything on progression-free survival for a faster FDA path. Pfizer is holding firm on overall survival as a primary endpoint, wagering that proving patients live longer will be the knockout punch. Same drug class, opposite philosophies.
Read more →Gilead Finally Reveals the Data Behind Its $3.15 Billion Bet
Before anyone outside the company had seen the numbers, Gilead paid $3.15 billion for Tubulis. At ASCO, the data went public: TUB-040 posted a 61% response rate and 11-month median progression-free survival in platinum-resistant ovarian cancer, nearly double what current options deliver. Crucially, no significant lung or eye toxicity, dodging the side effects plaguing rival ADCs.
Read more →Lung Cancer's Three-Horse Race Heats Up at AACR
AACR 2026 delivered a triple feature. Merck's MK-2010 (its $588 million PD-1/VEGF bispecific) posted a 55% unconfirmed response rate in first-line NSCLC. Nuvation's taletrectinib showed a jaw-dropping 49.7-month median duration of response for ROS1-positive patients. And Nuvalent's zidesamtinib proved it can rescue patients who've failed every other targeted therapy, with a 41-47% response rate at the end of the line.
Read more →Regulatory and Policy
The First Pill That Prevents COVID After Exposure Nears FDA Decision
For four years, people exposed to COVID had no approved pill to prevent infection. That gap may soon close. Shionogi's Xocova (ensitrelvir) is under FDA review for post-exposure prophylaxis, with a PDUFA action date of June 16, 2026, backed by NEJM-published data showing a 67% reduction in symptomatic COVID (76% in high-risk patients). It's once daily for five days, skips the drug-interaction headaches of Paxlovid, and fills a role no other oral antiviral covers.
Read more →The FDA Keeps Changing Its Mind, and Rare Disease Biotechs Are Paying the Price
The FDA approved rare disease drugs at a record clip in 2025, yet surprise rejections, reversed decisions, and canceled meetings are rattling the companies behind those treatments. A staggering 84% of biotech investors say they've pulled back on rare disease funding because of regulatory unpredictability. One company, Kezar Life Sciences, was forced to sell itself after the FDA canceled a critical meeting without explanation.
Read more →Money, Markets, and Machines
Biotech's Favorite Trick for Pretending Valuations Haven't Dropped
Instead of raising new funding rounds (which would force painful markdowns), biotech startups are quietly reopening old rounds at the same valuation. Many recent disclosed equity rounds have been follow-ons rather than fresh financings. U.S. VC-backed biotech deals fell 25% in 2025 to just 237. The public market rally hasn't trickled down to private companies still carrying 2021-era valuations.
Read more →Confidence Is Surging. The Job Market Didn't Get the Memo.
The Biopharma Sentiment Index hit 90 in Q1 2026, its highest reading since the post-pandemic downturn, fueled by M&A that could top $150 billion this year. But layoffs rose 16% in 2025 while affected workers surged 47%. Large pharma is hiring cautiously; small biotechs are running skeleton crews where a single failed trial can mean clearing out the office.
Read more →Pharma Pours $10 Billion Into AI, Still Waiting for the First Approved Drug
AI-designed drug candidates are posting 80-90% Phase I success rates, nearly double the historical average. AstraZeneca, Lilly, Novartis, and Sanofi have collectively committed over $10 billion in AI partnerships. Novartis collapsed a six-week process into a two-hour meeting. But zero AI-discovered drugs have reached full FDA approval yet, and Phase II success rates remain stubbornly average.
Read more →